Research uncovers key difference between our bodies' fight against viruses and bacteria

January 12, 2014

Scientists at The University of Nottingham have discovered a key difference in the biological mechanisms by which the immune system responds to viral and bacterial pathogens.

The study, published in the journal Nature Immunology and led by Professor Uwe Vinkemeier in the University's School of Life Sciences, centred on STAT1, a protein that can bind DNA and hence plays a vital role in regulating genes in the body.

STAT-1 responds to interferon signals, hormone-like molecules which control communication between cells to trigger defensive action by the body's immune system when pathogens such as bacteria, viruses, or parasites are detected. These powerful defensive actions are also part of the body's ability to control the growth of malignant tumours that can ultimately achieve their complete elimination.

It was previously thought that all interferons used single STAT1-containing units rather than STAT1 chains to regulate the activity of genes. However, using mice bred specially to express a mutated form of STAT1 which is limited to forming single STAT1 units, the Nottingham team has demonstrated that this abolishes the function of some interferons while leaving others largely unaffected.

They found that when the assembly of STAT1 chains was inhibited, type I interferons responsible for protecting against viruses such as were unaffected, whereas type II interferons, which protect against bacterial infections such as listeria, no longer functioned effectively.

Professor Vinkemeier said: "The core of these findings is that we are revising a central aspect of what we thought we knew about how these proteins worked. The molecular mechanisms underlying type I and type II interferon functioning are actually more distinct than we previously imagined. This in turn offers new options for rational pharmacological intervention."

For example, type I interferons, involved in the anti-viral response also play a role in stopping cells from growing and replicating—and therefore inhibiting the spread of the virus throughout the body. These interferons are already in clinical use against Hepatitis virus and several cancers and in the treatment of auto-immune diseases like . Type-II interferon, in contrast, has been shown to be detrimental in some of these conditions, namely multiple sclerosis and melanoma, an aggressive type of skin cancer.

"In situations like these our finding offers a new target for making current treatments more effective. There is good reason to assume that an inhibitor of STAT1 chain formation could potentially block detrimental type-II responses while keeping type I activities, including anti-viral protection, intact. This would avoid an important shortcoming of current STAT1 inhibitors."

Explore further: Genetic diversity: Crucial for our survival in many ways

More information: Paper: dx.doi.org/10.1038/ni.2794

Related Stories

Genetic diversity: Crucial for our survival in many ways

December 20, 2011
(Medical Xpress) -- Thanks to the sequencing of the 27 known human interferon genes, researchers from the Institut Pasteur and the CNRS reconstruct the genetic history of these proteins so central for our immune system, and ...

A first in front line immunity research

July 21, 2013
Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.

Study identifies protein essential for immune recognition, response to viral infection

November 24, 2013
A Massachusetts General Hospital (MGH)-led research team has identified an immune cell protein that is critical to setting off the body's initial response against viral infection. The report that will be published in an upcoming ...

Recommended for you

Bioengineers imagine the future of vaccines and immunotherapy

December 14, 2017
In the not-too-distant future, nanoparticles delivered to a cancer patient's immune cells might teach the cells to destroy tumors. A flu vaccine might look and feel like applying a small, round Band-Aid to your skin.

Immune cells turn back time to achieve memory

December 13, 2017
Memory T cells earn their name by embodying the memory of the immune system - they help the body remember what infections or vaccines someone has been exposed to. But to become memory T cells, the cells go backwards in time, ...

Steroid study sheds light on long term side effects of medicines

December 13, 2017
Fresh insights into key hormones found in commonly prescribed medicines have been discovered, providing further understanding of the medicines' side effects.

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

Researchers bring new insight into Chediak-Higashi syndrome, a devastating genetic disease

December 12, 2017
A team of researchers from the National Institutes of Health and University of Manchester have uncovered new insights into a rare genetic disease, with less than 500 cases of the disease on record, which devastates the lives ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.